Skip to main content
. 2016 Feb 15;2016:7508026. doi: 10.1155/2016/7508026

Figure 5.

Figure 5

Association between PPARα and metabolic and structural anomalies. Results of analyses for patients Group (I): (a) PPARα and GLUT-4 mRNA for patients Group (I) and for all hearts with HF: (b) PPARα and FAT/CD36 mRNA; (c) PPARα and CPT; (d) FAT/CD36 mRNA and LVEF and for patients Group (II): (e) PPARα mRNA and cell degeneration and (f) PPARα mRNA and serum NT-proBNP level.